The patient is a 71 year old male with no past medical history who was admitted for back pain. Investigations confirmed spondylodiscitis of the L4 and L5 vertebrae with methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia. He was started on intravenous (IV) vancomycin and underwent posterior L4 – L5 decompression, following which he was started on oral rifampicin in November 2020, to be continued for one year.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact.Indian J. Nephrol. 2016; 26: 322-328
- Pregnane X Receptor Activator Rifampin Increases Blood Pressure and Stimulates Plasma Renin Activity.Clin. Pharmacol. Ther. 2020; 108: 856-865
- Resistant hypertension during antituberculosis treatment: how is rifampicin implicated?.Med. J. Malaysia. 2020; 75: 591-593
Publication stageIn Press Journal Pre-Proof
I confirm that the author had access to the data and participated in the preparation of this manuscript.
© 2022 Published by Elsevier Inc.